Boiling and ready to burst as Titan Pharmaceuticals Inc. (TTNP) last month performance was -23.19%

At the end of the latest market close, Titan Pharmaceuticals Inc. (TTNP) was valued at $0.22. In that particular session, Stock kicked-off at the price of $0.195 while reaching the peak value of $0.2344 and lowest value recorded on the day was $0.1925. The stock current value is $0.21.

Recently in News on September 15, 2020, Titan’s Probuphine® Commercialization Partner, Molteni, Enters Into Exclusive European Distribution Agreement With Accord Healthcare. Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that its partner, Molteni Farmaceutici (“Molteni”), has entered into an exclusive distribution agreement with Accord Healthcare Europe (“Accord”) for the commercialization of Sixmo®-(6-months buprenorphine implant), the brand name for Probuphine® in the European Union (“EU”). You can read further details here

Titan Pharmaceuticals Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $0.5450 on 03/03/20, with the lowest value was $0.1703 for the same time period, recorded on 09/04/20.

Titan Pharmaceuticals Inc. (TTNP) full year performance was -41.54%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Titan Pharmaceuticals Inc. shares are logging -64.91% during the 52-week period from high price, and 45.49% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.14 and $0.59.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 4253549 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Titan Pharmaceuticals Inc. (TTNP) recorded performance in the market was 10.77%, having the revenues showcasing -37.30% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 21.07M, as it employees total of 21 workers.

The Analysts eye on Titan Pharmaceuticals Inc. (TTNP)

During the last month, 0 analysts gave the Titan Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.2883, with a change in the price was noted -0.0269. In a similar fashion, Titan Pharmaceuticals Inc. posted a movement of -11.43% for the period of last 100 days, recording 10,160,822 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for TTNP is recording 3.06 at the time of this writing. In addition, long term Debt to Equity ratio is set at 2.06.

Technical rundown of Titan Pharmaceuticals Inc. (TTNP)

Raw Stochastic average of Titan Pharmaceuticals Inc. in the period of last 50 days is set at 20.14%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 34.82%. In the last 20 days, the company’s Stochastic %K was 28.40% and its Stochastic %D was recorded 24.18%.

Considering, the past performance of Titan Pharmaceuticals Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 10.77%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -4.02%, alongside a downfall of -41.54% for the period of the last 12 months. The shares increased approximately by 7.50% in the 7-day charts and went up by -23.19% in the period of the last 30 days. Common stock shares were lifted by -37.30% during last recorded quarter.